Pembrolizumab
Cold Chain RequiredFDA Approved
Contents
Description
Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of certain cancers. It works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing PD-1 mediated inhibition of the immune response.
Indications & Therapeutic Use
Anaplastic thyroid cancer, Transitional cell carcinoma of the corpus uteri
Global Availability (3 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Pembrolizumab — GNH India
28 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Keytruda
100mg/4mlvialsUSA
Keytruda 100mg
100mg/4mlvialsNetherlands
Keytruda 100mg-AU
100mg/4mlvialsAustralia
Keytruda 100mg-TU
100mg/4mlvialsIreland
Keytruda 100mg/4ml
100mg/4mlvialsUSA
Keytruda 25mg/ml
25mg/ml X 4mlvialsGermany
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Pembrolizumab
| Generic Name | Pembrolizumab |
| Brands | 1 brand available |
| Active Ingredient | Pembrolizumab |
| Drug Class | Anaplastic thyroid cancer |
| Manufacturer | Merck |
| Dosage Forms | Injection |
| Medical Code | L01FF02 |
| Orphan Status | No |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Countries | 3 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations4 Validated Nodes